NewsBenzingaReported Saturday, Genmab Reports Rina-S Showed 45.9% ORR, 9.5-Month mPFS And 12.1-Month mDOR In Platinum-Resistant Ovarian Cancer, With Activity Regardless Of FRα Expression Levels Reported Saturday, Genmab Reports Rina-S Showed 45.9% ORR, 9.5-Month mPFS And 12.1-Month mDOR In Platinum-Resistant Ovarian Cancer, With Activity Regardless Of FRα Expression Levels Benzinga 2026.10.05 06:56 (GMT+0) Open on Benzinga Other news Morgan Stanley Upgrades Wells Fargo to Overweight, Maintains Price Target to $102 Vivek Ramaswamy-Founded Strive to Acquire More Bitcoin? Here's What the CEO Hinted at BMO Capital Initiates Coverage On Vertiv Holdings with Outperform Rating, Announces Price Target of $329 BMO Capital Initiates Coverage On nVent Electric with Outperform Rating, Announces Price Target of $212 Sweetgreen Q2 2026 Earnings Call: Complete Transcript Gen Digital Q1 2027 Earnings Call: Complete Transcript
BMO Capital Initiates Coverage On Vertiv Holdings with Outperform Rating, Announces Price Target of $329
BMO Capital Initiates Coverage On nVent Electric with Outperform Rating, Announces Price Target of $212
